GlassScriptPhysician profile
Alicia M Jones
NPI 1720220650
$2,851.04
in general payments reported to CMS, 2019-2025
29 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $297 · 2021: $292 · 2022: $51.75 · 2023: $200 · 2024: $602 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $701.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $377.92 | 2021-2025 | |
| Novo Nordisk INC | $337.49 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $160.47 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $145.20 | 2020-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $141.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.17 | 2021 | |
| Pfizer INC. | $102.41 | 2019-2025 | |
| Exact Sciences Corporation | $101.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $99.76 | 2019-2025 | Shingrix, Arexvy |
| Janssen Biotech, INC. | $82.52 | 2019-2021 | |
| Amgen INC. | $67.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $48.20 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $44.64 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $34.06 | 2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $32.46 | 2019 | |
| Dynavax Technologies Corporation | $31.96 | 2019-2022 | |
| Radius Health, INC. | $29.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.47 | 2024 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $20.05 | 2023 | |
| Optinose US, INC. | $18.56 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $18.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.99 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $16.77 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.20 | 2025 | Gvoke Hypopen |
| Lifescan, INC. | $13.24 | 2019 | |
| Allergan, INC. | $12.89 | 2019 | |
| Sanofi Pasteur INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.